ACSS2 is highly expressed in numerous tumours and several studies have shown that genetic depletion or pharmacological targeting of ACSS2 inhibits tumour growth in breast, prostate, liver, pancreatic, ovarian and skin cancers and glioblastoma [206,207,208,282,283]. Here, ACSS2 is linked to glioblastoma.